InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,480.10
(
0.28%
)
US TECH 100
19,162.00
(
-0.24%
)
Dow Jones
39,501.94
(
0.90%
)
Brent Oil
84.85
(
0.98%
)
Bitcoin
61,283.85
(
-2.97%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 180

Wednesday, 05/30/2018 10:33:19 AM

Wednesday, May 30, 2018 10:33:19 AM

Post# of 438
GNCA has lost 85% of its value since the unexpected 9/17 pivot to immuno-oncology

H1/2019 is the expected time frame to read out Ph1 data from their lead neoantigen cancer vaccine.

Q1/18 cash = $51.2mn and they are tapping their ATM. Runway extends into Q4/2019

Optimism revolves around the fact that their HSV vaccine reduced viral shedding despite not being marketable.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up